RT Journal Article
SR Electronic
T1 Impact of digital assistive technologies on the quality of life for people with dementia: A scoping review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.02.23296434
DO 10.1101/2023.10.02.23296434
A1 Schneider, Charlotte
A1 Nißen, Marcia
A1 Kowatsch, Tobias
A1 Vinay, Rasita
YR 2023
UL http://medrxiv.org/content/early/2023/10/03/2023.10.02.23296434.abstract
AB Background Digital assistive technologies (DATs) have emerged as promising tools to support the daily life of people with dementia (PWD) by offering support in various aspects of daily life. Quality of life (QOL) is an important consideration when discussing the care of PWD in relation to their autonomy. Current research tends to concentrate either on specific categories of DATs, or provide a generic view. Therefore, it would be of essence to provide a review of the different kinds of DATs, and how they contribute to improving QOL for PWD.Objective This scoping review aimed to review DATs and their impact on QOL for PWD.Method For this scoping review a broad literature search was performed in Cochrane, Embase, PubMed, Scopus, and Web of Science, covering scientific literature from January 2013 and May 2023. Screening and data extraction were conducted, followed by quantitative and qualitative analysis using thematic analysis principles and Digital Therapeutics (DTx) Alliance categories for DAT grouping.Results The literature search identified 6’083 records, with 1’056 duplicates. After screening, 4’560 full-texts were excluded, yielding 122 studies of different designs. The DATs were categorized into digital therapeutics (n=109), patient monitoring (n=30), digital diagnostics (n=2), care support (n=2), and health system clinical software (n=1). These categories were identified to impact various aspects of QOL: preserving autonomy, engagement, and social interaction, health monitoring and promotion, improving activities of daily living, improving cognition, maintaining dignity, managing behavioral and psychological symptoms of dementia (BPSD), and safety/surveillance.Conclusions Various DATs offer extensive support, elevating the QOL of PWD. Digital therapeutics are predominantly used for aging-in-place and independent living through assistance with daily tasks. Future research should focus on less-represented DHT categories, such as care support, health & wellness or software solutions. Observing ongoing DAT developments and their long-term effects on QOL remains essential.Strengths and limitations of this studyThe study conducted an extensive search across five electronic databases spanning a decade to identify relevant literature on DATs and their impact on the QOL for PWD.By excluding conference proceedings, book chapters, pilot, and feasibility studies, the review might have missed ongoing or planned research that could offer insights into different DATs or QOL impacts.While the scoping review approach allowed for a broad overview, it didn’t assess the quality of included studies or intervention effectiveness, potentially introducing bias and limiting in-depth analysis.The study’s emphasis on patient-facing DATs could have introduced bias, highlighting digital therapeutics in the included literature while potentially overlooking other assistive technology categories.Competing Interest StatementMN and TK are affiliated with the Centre for Digital Health Interventions (CDHI), a joint initiative of the Institute for Implementation Science in Health Care, University of Zurich, the Department of Management, Technology, and Economics at ETH Zurich, and the Institute of Technology Management and School of Medicine at the University of St.Gallen. CDHI is funded in part by CSS, a Swiss health insurer. TK is also a co-founder of Pathmate Technologies, a university spin-off company that creates and delivers digital clinical pathways. However, neither CSS nor Pathmate Technologies was involved in this research. All other authors declare no conflict of interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript